NIM
CLDX icon

NEOS Investment Management’s Celldex Therapeutics CLDX Stock Holding History

NEOS Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,261
Closed -$512K – 604
2024
Q4 		$512K Sell
20,261
-6,331
-24% -$172K 0.01% 505
2024
Q3 		$904K Sell
26,592
-1,943
-7% -$74K 0.03% 393
2024
Q2 		$1.06M Buy
28,535
+16,625
+140% +$627K 0.04% 320
2024
Q1 		$500K Buy
11,910
+350
+3% +$14.4K 0.03% 383
2023
Q4 		$458K Buy
+11,560
New +$340K 0.04% 300

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NEOS Investment Management's CLDX Position: Q1 2025 in Review

NEOS Investment Management sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 20,261 shares — an estimated $512K sold.

NEOS Investment Management first reported a position in CLDX in Q4 2023 and held it in 5 quarters. The position peaked at $1.06M in Q2 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • NEOS Investment Management reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • NEOS Investment Management sold 20,261 Celldex Therapeutics shares in Q1 2025, an estimated $512K.
  • NEOS Investment Management first reported a position in Celldex Therapeutics in Q4 2023 and held it in 5 quarters.
  • NEOS Investment Management's Celldex Therapeutics position peaked at $1.06M in Q2 2024.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on NEOS Investment Management's 13F filing for Q1 2025, filed 15 May 2025.